Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7999 in healthy adults
NCT05481333Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN7999 in beta thalassemia and iron overload (8 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment emergent adverse events at 26 weeks. Started Oct 2022; status: completed.
02
Drugs
REGN7999
03
Conditions
beta thalassemiairon overload
Beyond the preview
Go deeper on NCT05481333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481333.